Three independent discounted-cash-flow-style models value Amneal Pharmaceuticals, Inc. Class A Common Stock every trading day. 0 of 3 currently price AMRX above its market price.
| Free Cash Flow model | $-7.61 |
| Excess Profit model | $-18.48 |
| Residual Earnings model | $-0.09 |
| Dividend Discount model | — |
| Piotroski F-Score | 7 / 9 |
| Return on invested capital | +12.4% |
| Net debt / EBITDA | 5.8× |
| Gross margin | +36.9% |
| Revenue CAGR | +10.9% |
| Cash conversion | 2.7× |
| Dividend yield | — |
| Buyback yield | -1.4% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open AMRX in StockKitty